Key result
TAVI evolution linked to a ~3-point absolute reduction in 30-day cardiovascular mortality over time.
Why the study?
How have patient characteristics, procedural safety, and clinical outcomes evolved over 7 years of TAVI practice in patients with severe aortic stenosis?
Cohort (n=2,000)
No
How have patient characteristics, procedural safety, and clinical outcomes evolved over 7 years of TAVI practice in patients with severe aortic stenosis?
Answers are grounded in this paper and cite their sources.
Over a 7-year period, TAVI practice evolved towards treating lower-risk patients, accompanied by a rapid progression towards improved procedural safety and reduced 30-day cardiovascular mortality.
OBJECTIVES: Use of transcatheter aortic valve implantation (TAVI) to treat severe aortic stenosis (AS) has gained popularity, accompanied by an evolution of patient and clinical factors. We aimed to characterise changes and evaluate their impact on outcomes. SETTING: In this single-centre, German TAVIK registry patients undergoing TAVI between 2008 and 2015 were documented prospectively. PARTICIPANTS/INTERVENTIONS: 2000 consecutive patients with AS undergoing TAVI were divided in four cohorts. 500 patients underwent TAVI in each of the following time bins: April 2008 to July 2010 (cohort I), July 2010 to April 2013 (cohort II), April 2012 to October 2013 (cohort III) and October 2013 to March 2015 (cohort IV). RESULTS: The mean age was 81.8 years, without significant variation across cohorts. Compared with cohort I, prior MI (5.4%vs11.0%; p<0.001) and New York Heart Association class IV (10.0%vs3.6%; p<0.001) were less common in cohort IV. Across cohorts, there was a fall in EuroSCORE (24.3%-18.7%), frailty (48.4%-17.0%) and use of transapical access (43.6%-29.0%), while transfemoral access increased (56.4%-71.0%; p<0.001 for each). Periprocedurally, there was a fall in moderate/severe aortic regurgitation (3.2%-0.0%) and rate of unplanned cardiopulmonary bypass (4.0%-1.0%; both p<0.001). A similar trend applied to 30-day rate of major vascular complications (5.2%-1.8%; p=0.006), life-threatening bleeding (7.0%-3.0%; p<0.001) and cardiovascular mortality (4.4%-1.8%; p=0.020). One-year post-TAVI, mortality and stroke rates did not differ. CONCLUSIONS: Evolution of TAVI between 2008 and 2015 saw a trend towards its usage in lower risk patients and rapid progression towards improved safety. Evaluation and refinement should now continue to further lessen stroke and pacemaker rates.
No takes yet. Share an insight, caveat, or question.
Schymik et al. (2018) conducted a cohort in Severe aortic stenosis (n=2,000). Transcatheter aortic valve implantation (TAVI) in later time period (Cohort IV: Oct 2013-Mar 2015) vs. TAVI in earlier time period (Cohort I: Apr 2008-Jul 2010) was evaluated on VARC-2 early safety composite endpoint at 30 days (p=0.068). Evolution of TAVI from 2008 to 2015 reduced 30-day cardiovascular mortality, life-threatening bleeding, and major vascular complications.
Synapse has enriched 10 related papers. Consider them for comparative context: